 NAPLES, Fla., Sept. 17, 2021 PRNewswire -- Enveric Biosciences NASDAQ: ENVB Enveric or the Company, a patient-centric biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced the closing of its acquisition of MagicMed Industries Inc. MagicMed, a privately-held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, N,N-dimethyltryptamine DMT and other molecular derivatives with applications across multiple indications, in an all-stock transaction. 